Market Overview

UPDATE: Bank of America Maintains Onyx Pharmaceuticals at Buy on Latest Kyprolis Data

Related ONXX
How to Prepare for the New Year
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

Bank of America reiterated Onyx Pharmaceuticals (NASDAQ: ONXX) at Buy with a $99 price objective.

Bank of America said, "November IMS sales for ONXX's multiple myeloma drug Kyprolis were $9.8M, below $10.0M reported in October. As we have noted previously, it is difficult to extrapolate actual sales from IMS data because IMS does not have access to sales information from all key wholesalers. … Management commentary in early December gave us the impression to expect growth from new prescribers to more than offset loss of the initial bolus seen early in the launch, so we are not changing our model at this time."

Onyx Pharmaceuticals closed at $75.64 on Friday.

Latest Ratings for ONXX

Nov 2013Stifel NicolausTerminates
Aug 2013Maxim GroupDowngradesBuyHold
Aug 2013Summer StreetDowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (ONXX)

View Comments and Join the Discussion!